Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVERICK
2024-518817-24-01Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing Mannitol with Normal saline (placebo) (2 arms). Primary endpoint: Days to kidney function. Planned start Apr 2025; status: authorised.
02
Drugs
Bronchitol
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2024-518817-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518817-24-01.